Swiss pharma giant Roche’s (ROG: SIX) Genentech subsidiary has appointed Alexander Hardy as chief executive, effective March 1, 2019.
Mr Hardy first joined Genentech in 2005, where he held several senior management positions, including leading patient access services and overseeing commercial operations for a range of therapeutic areas from HER2-positive cancer to influenza and neuroscience.
In 2014, he became head of Asia Pacific for Roche Pharmaceuticals and is currently head of global product strategy. Mr Hardy succeeds Bill Anderson, who was recently appointed chief executive officer, Roche Pharmaceuticals, replacing Daniel O’Day, who is moving to Gilead Sciences as CEO of the US biotech firm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze